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Abstract
Background: It has been suggested that haptoglobin polymorphism may influence the pathogenesis of microvascular 
and macrovascular complications in diabetic patients. 
Objective: This cross sectional study was carried out to investigate the existence or not of an association between 
haptoglobin genotypes and prevalence of ischemic cardiovascular events (stable angina, unstable angina and acute 
myocardial infarction), systemic arterial hypertension, refractory hypertension, obesity and dyslipidemia in 120 
type-2 diabetes mellitus patients followed up at Hospital de Clínicas da UNICAMP in Campinas, São Paulo state, 
southeastern Brazil.
Methods: Haptoglobin genotyping was performed by allele-specific polymerase chain reactions. The frequencies of 
the haptoglobin genotypes were compared with the presence/absence of cardiovascular disease, systemic arterial 
hypertension, refractory hypertension, obesity and dyslipidemia; systolic and diastolic blood pressure measurements; 
plasma levels of glucose, cholesterol (total, high density lipoprotein-HDL and low density lipoprotein-LDL) and 
triglycerides; and serum creatinine levels. 
Results: Although no association between haptoglobin genotype and the presence of cardiovascular disease could be 
identified, we found a significant excess of patients with Hp2-1 genotype among those with refractory hypertension, who 
also had higher systolic and diastolic blood pressure, and total and LDL cholesterol levels.
Conclusion: Our results suggest that type-2 diabetes mellitus patients with the Hp2-1 genotype may have higher 
chances of developing refractory hypertension. Further studies in other diabetic populations are required to confirm 
these findings. (Arq Bras Cardiol 2011;97(4):338-345)
Keywords: Haptoglobins; hypertension; myocardial infarction; obesity; dyslipidemias; diaebtes mellitus, type 2.
Introduction
Type 2 diabetes mellitus (T2DM) is a metabolic disorder 
caused by insulin resistance and beta-cell dysfunction. It 
is associated with high risk of developing cardiovascular 
disease (CVD) 1,2. The diabetic milieu resulting from chronic 
hyperglycemia can generate advanced glycation end products 
and enhance oxidative stress, contributing directly to the 
progression of diabetic complications and CVD3. In addition, 
lipoproteins are oxidatively modified into oxidized low-density 
lipoproteins, stimulating the production of inflammatory 
cytokines responsible for some of the pathological changes 
implicated in the initiation and development of coronary heart 
disease, which is caused mainly by atherosclerosis4,5. 
Classic CVD risk factors and other recently discovered 
factors such as inflammation and oxidative stress associated 
with the diabetic state, however, are not sufficient to 
explain the occurrence of these complications, suggesting 
that genetic susceptibility factors influencing both glucose 
homeostasis and the development of atherosclerosis may 
be involved6-8.
Haptoglobin (Hp) is a glycoprotein with antioxidant 
and immunomodulatory properties. In humans, the Hp 
locus is on the long arm of chromosome 16 (16q22) 
and is polymorphic, with two main alleles (HP1 and 
HP2) resulting in three distinct genotypes/phenotypes 
(Hp1-1, Hp2-1 and Hp2-2)9,10. The Hp proteins have 
distinct biochemical and biophysical properties, and this 
polymorphism has been associated with the susceptibility 
to and outcome of several human pathologies11-13. The 
most firmly established biological function of Hp is its 
strong binding to free hemoglobin (Hb)10,14. Clearance 
of the Hp-Hb complex can be mediated by the CD 
163 scavenger receptor present in monocytes and 
macrophages. However, some changes in the glycosylation 
pattern of Hb that occur in diabetic patients may interfere 
with the binding of this complex to macrophages15.
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It has been suggested that diabetic patients carrying 
the Hp2-2 genotype have increased risk of developing 
CVD16-20. However, this does not seem to be a consensual 
observation, and would appear to depend on the population 
and aspects analyzed. As far as we know, there are few 
studies investigating the influence of Hp polymorphism on 
the occurrence of ischemic cardiovascular events, systemic 
arterial hypertension (SAH), refractory hypertension (RH), 
obesity and dyslipidemia, and none of these include 
Brazilian patients with DM. Therefore, this is the main 
aim of this study.
Methods
After obtaining approval from the Local Ethics Committee, 
we collected peripheral blood samples from 120 T2DM 
patients with at least 10 years of disease followed at the 
Endocrinology Section of Hospital de Clínicas da UNICAMP 
in Campinas who had previously been investigated in another 
study21 in the state of São Paulo, southeastern Brazil. All 
patients signed an Informed Consent Form. Pregnant patients 
and those aged 76 years or older were excluded from the 
study. The study was a cross-sectional one and was designed 
to investigate a possible association between Hp type and 
the prevalence of ischemic complications, such as stable 
angina, unstable angina and acute myocardial infarction 
with ST segment elevation and/or high markers of myocardial 
necrosis. Cardiovascular risk was assessed in the general 
group only. The presence of coronary artery disease was 
related to suggestive symptoms, including claudication on 
exertion, abnormal electrocardiogram (ECG), positive tests 
inducing ischemia or coronary angiography with obstructive 
disease. The absence of symptoms and findings described 
above were taken as the absence of clinically significant 
cardiovascular disease22.
Stable angina was diagnosed by the presence of 
cardiac symptoms in a pattern that remained constant in 
presentation, frequency, character and duration over time 
and coronary disease at coronary angiography. Unstable 
angina was diagnosed by the presence of new cardiac 
symptoms and positive electrocardiogram (ECG) findings with 
normal biomarkers or a changing pattern of symptoms and 
positive ECG findings with normal biomarkers and coronary 
disease at coronary angiography. Acute myocardial infarction 
was diagnosed by ECG or diagnostic biomarkers23.  Type 
2 diabetes mellitus patients were divided into a group of 
50 patients with CVD (42% males; 80% whites; aged from 
42 to 75 years) and another group of 70 patients without 
CVD (37.14% males; 86.6% whites; aged from 48 to 75 
years). All data were obtained from the patients’ medical 
records after cardiological evaluation by a physician from 
the Clinical Cardiology Section of Hospital de Clínicas da 
UNICAMP. The demographic and clinical data of these 
patients and information on the medication they were taking 
are summarized in Table 1.
The frequencies of Hp genotypes were compared with 
the presence/absence of SAH, RH, obesity and dyslipidemia; 
systolic and diastolic blood pressure (SBP and DBP) 
measurements; plasma levels of glucose, cholesterol (total, 
HDL and LDL) and triglycerides; and serum creatinine. The 
whole group of T2DM patients was also compared with a 
control group of 142 healthy individuals (36% males; 78% 
whites; ages 18–62 years) who had previously been studied24. 
This group consisted of university students and employees 
living in the same region as the patients, who have accepted 
to participate in the study. 
Our definition of diabetes mellitus was based on clinical 
features	 and	 fasting	 glucose	 of	 ≥	 126	mg/dL	 on	 two	
different occasions25. Glycosylated hemoglobin (HbA1C) was 
measured using the Bio-Rad Variant II high-performance 
liquid chromatography system (Bio-Rad, Hercules, CA, 
USA) (normal range 4.5% — 6.2%). Systemic arterial 
hypertension was considered to be present if the SBP was 
>130 mm Hg and/or DPB was >90 mm Hg, and were 
measured in a medical visit to the Cardiology Section 
of Hospital de Clínicas da Unicamp. Ambulatory blood 
pressure monitoring (ABPM) was not performed. Refractory 
hypertension was considered to be present in patients being 
treated with three different antihypertensive medications 
(ideally including one diuretic drug) at effective doses if SBP 
>130 mm Hg and DPB >80 mm Hg26. Dyslipidemia was 
identified according to the National Cholesterol Education 
Program (NCEP) III guidelines as total cholesterol levels 
≥200	mg/dL,	or	HDL	<40	mg/	dL	for	men	and	<50	mg/
dL	for	women,	or	triglycerides	≥150	mg/dL27. Cholesterol 
and triglyceride levels were measured by enzymatic 
colorimetric assay in the Roche-Hitachi modular system 
(Roche Diagnostics, Mannheim, Germany). Obesity was 
defined as body mass index (BMI) 30 kg/m2 28. Diabetic 
retinopathy (DR) and diabetic nephropathy (DN) had 
been previously investigated in these patients21,29. Serum 
creatinine was measured by a modified Jaffé method, and 
the	 reference	 values	 for	males	 and	 females	were	≤1.20	
mg/dL	and	≤0.90	mg/dL,	respectively30. 
Genomic DNA samples were obtained from peripheral 
blood leukocytes (GFX Genomic Blood Purification kit, 
GE Healthcare, UK), and Hp genotyping was performed 
by allele-specific polymerase chain reaction, according to 
Yano et al31.
Statistical analyses were performed with Statistical Analysis 
System 8.02 for Windows, SAS Institute Inc., Cary, NC, 
USA. Chi-square (c2) test and Fischer exact test were used 
to determine whether there was an association between 
the categorical variables. The results of Hardy-Weinberg 
equilibrium were also obtained with the χ2-test. Mann-
Whitney and ANOVA tests were used to compare continuous 
variables. Unadjusted univariate logistic regression and 
multivariate logistic regression adjusted for sex and age were 
used to test an association between RH and some potential 
risk factors. P-values < 0.05 were considered statistically 
significant. Alpha-error of 5%, b-error of 20% and test 
power equal or above 80% for all statistical analyses were 
considered cut-off values for significance level. 
Results
Table 1 shows that there is a significant difference 
between the diabetic patients with and without CVD in 
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Table 1 – Demographic characteristics (mean ± S.D.), clinical data and patterns of drug use among diabetic patients with and without CVD
Variables T2DM patients with CVD (n = 50) T2DM patients without CVD (n = 70) p-values
Age, years 66.0±6.61 62.7±7.94 0.0319
Males, n (%) 21(44.7) 26(55.3) 0.5910
Whites, n (%) 32(35.6) 58(64.4) 0.3686
Duration of DM (years) 19.2±6.52 18.1±6.41 0.2568
Smoking, n (%)
Yes 9(18.0) 4(5.7)
0.0328
No 41(82.0) 66(94.3)
T2DM history in the family, n (%)
Yes 4(8.0) 2(2.9)
0.2331
No 46(92.0) 68(97.2)
SAH, n (%)
Yes 49(98.0) 59(84.3)
0.0136
No 1(2.00) 11(15.7)
RH, n (%)
Yes 35(70.0) 51(72.9)
0.7320
No 15(30.0) 19(27.1)
Dyslipidemia, n (%)
Yes 42(84.0) 43(61.4)
0.0073
No 8(16.0) 27(38.6)
Obesity, n (%)
Yes 18(36.0) 23(32.9)
0.7204
No 32(64.0) 47(67.1)
DR, n (%)
Yes 34(68.0) 41(58.6)
0.2929
No 16(32.0) 29(41.4)
DN, n (%)
Yes 32(64.0) 30(42.9)
0.0223
No 18(36.0) 40(57.1)
Neuropathy, n (%)
Yes 27(54.0) 27(38.6)
0.0940
No 23(46.0) 43(61.4)
Antihypertensive therapy, n (%)
Yes 50(100.0) 57(81.4)
0.0013
No 0(0.00) 13(18.6)
Antihyperlipidemic therapy, n (%)
Yes 31(62.0) 32(45.7)
0.0782
No 19(38.0) 38(52.3)
Oral antidiabetic therapy, n (%)
Yes 29(58.0) 50(71.4)
0.1262
No 21(42.0) 20(28.6)
Aspirin, n (%)
Yes 47(94.0) 39(55.7)
0.0001
No 3(6.00) 31(44.3)
*S.D.- standard deviation; T2DM - Type 2 diabetes mellitus ; CVD - developing cardiovascular disease; SAH - Systemic arterial hypertension; RH - refractory hypertension; 
DR - Diabetic retinopathy; DN - Diabetic nephropathy.
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terms of age (the mean age of the latter group is lower) 
and smoking habit (a higher percentage in the first group), 
as well as the presence of SAH, dyslipidemia and DN and, 
as expected, the use of antihypertensive drugs and aspirin.
A comparison of the frequencies of Hp genotypes in 
the two groups of patients and in the complete group of 
patients and the control group are shown in Table 2. Both 
groups of patients were in Hardy-Weinberg equilibrium 
(p = 0.5962) and no significant association was found.
However, when we compared the frequency distribution 
of the Hp genotype with the presence/absence of SAH, RH, 
obesity and dyslipidemia and SBP, DPB and the laboratory 
parameters, we found a prevalence of Hp2-1 patients 
with RH (p = 0.0104), as well as significant differences 
in SBP, DBP and total and low density lipoprotein (LDL) 
cholesterol (p values of 0.0113, 0.004, 0.0006 and 0.0065, 
respectively) (Table 3).
Univariate logistic regression analysis was used to test an 
association between RH and age, sex, ethnic group, obesity, 
high levels of total and LDL- cholesterol, triglyceride and 
creatinine. The analysis showed that the prevalence of RH 
in T2DM patients with the Hp2-1 genotype differed from 
that in T2DM patients with the Hp2-2 genotype (95% CI, 
1.576-11.246; p = 0.0041; OR 4.210). This difference 
remained statistically significant in stepwise multiple logistic 
regression analysis (95% CI, 1.542-11.021; p = 0.0047; 
OR 4.123). These data are shown in Table 4.
Discussion
Diabetic state contributes to the initiation and progression 
of vascular complications, which remain the leading cause 
of mortality in diabetic patients32. Salles et al33 investigated 
mortality rates and predictors of mortality in Brazilian T2DM 
patients and found evidence that these patients have a more-
Table 2 – Haptoglobin genotype in a group of Brazilian diabetic patients with or without macrovascular complications and in healthy controls
Hp1-1 (%) Hp2-1 (%) Hp2-2 (%) p-values
T2DM with macrovascular complications (n=50) 28.0 46.0 26.0
0.6954
T2DM without macrovascular complications (n=70) 21.4 48.6 30.0
Patients (n=120) 24.2 47.5 28.3
0.6740
Controls  (n=142) 25.3 42.3 32.4
T2DM - Type 2 diabetes mellitus.
Table 3 – Presence/absence of SAH, RH, obesity and dyslipidemia; SBP and DBP (mean  ±  S.D.); and biochemical parameters (mean  ±  S.D.) 
of the T2DM patients divided according to Hp genotype
Blood Pressures, clinical and Biochemical data Hp1-1 Hp2-1 Hp2-2 p-values
T2DM with SAH (n=108) 24.1 49.1 26.8
0.4919
T2DM without SAH (n=12) 25.0 33.3 41.7
T2DM with RH (n=86) 22.1 55.8 22.1
0.0104
T2DM without RH (n=34) 29.4 26.5 44.1
T2DM with obesity (n=41) 24.4 56.1 19.5
0.2617
T2DM without obesity (n=79) 24.1 43.0 32.9
T2DM2 with dyslipidemia (n=85) 24.7 52.9 22.3
0.0630
T2DM2 without dyslipidemia (n=35) 22.9 34.3 42.8
SBP (mmHg) 137.7  ±  18.9 147.5 ± 18.1 137.7 ± 20.1 0.0113
DBP (mmHg) 81.9 ± 9.5 89.6 ± 16.2 81.8 ± 11.4 0.0064
Plasma glucose (mg/dl) 156.1 ± 70.9 147.5 ± 18.1 146.4 ± 81.5 0.4180
Total cholesterol (mg/dl) 166.2 ± 34.4 195.8 ± 46.8 188.3 ± 41.2 0.0006
HDL cholesterol (mg/dl) 44.7 ± 12.2 50.8 ± 16.2 50.1 ± 14.3 0.3303
LDL cholesterol (mg/dl) 88.6 ± 27.0 115.7 ± 42.9 106.4 ± 31.8 0.0065
Triglycerides 156.1 ± 77.0 190.3 ± 46.8 156.4 ± 72.8 0.7938
Serum creatinine (mg/dl) 1.16 ± 0.81 1.32 ± 1.10 1.02 ± 0.52 0.2114
T2DM - Type 2 diabetes mellitus; SAH - Systemic arterial hypertension; RH - refractory hypertension; SBP - diastolic blood pressure; DBP - Systolic blood pressure.
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than-three-fold excess mortality compared with the general 
population. According to the authors, this is partially explained 
by increased cardiovascular mortality. They also showed that 
some variables, such as older age, pre-existing vascular disease, 
increased 24h-proteinuria and decreased HDL cholesterol, are 
considered independent predictors of this increased mortality33.
 In this study, we found that the presence of CVD in T2DM 
Brazilian patients was associated with older age, cigarette smoking 
habit, SAH, dyslipidemia and development of DN. No significant 
differences were found for gender, duration of diabetes, family 
history of T2DM, RH, obesity or the presence of DR. 
Haptoglobin acts as an antioxidant by protecting against the 
action of free radicals, and its functional allelic polymorphism 
is correlated with differences in protection from vascular 
disease11. A number of studies have postulated that some 
characteristics of the diabetic state, such as high glycosylation of 
the Hb molecule and reduction in the proportion of monocytes 
expressing surface CD163, could impair the internalization of 
Hb-Hp complex, especially in diabetic patients with the Hp2-2 
phenotype. Furthermore, the oxidation of LDL by glycosylated 
Hb is apparently not completely blocked by its binding to Hp15.
It has been suggested that the Hp phenotype is an independent 
risk factor for CVD in patients with diabetes mellitus and that the 
Hp2-2 protein may provide less protection against vascular 
complications than the two other types of Hp17,19. Levy et al17 in 
a matched case-control analysis of the Strong Heart Study, which 
investigated a group of American Indians, observed that diabetic 
individuals with the Hp2-2 phenotype have five times more risk 
of developing CVD than those who have the Hp1-1 phenotype. 
An intermediate risk of CVD was found to be associated with 
the Hp 2-1 phenotype. However, no association was observed 
in individuals without diabetes mellitus17.
In addition, Suleiman et al19 demonstrated that the Hp 
phenotype is an important predictor of 30-day mortality and heart 
failure among individuals with diabetes and acute myocardial 
infarction. They found that diabetic patients with the Hp1-1 
phenotype had smaller infarction sizes, whereas patients with 
Hp2-1 and Hp2-2 phenotypes sustained larger infarctions and 
consequently had a higher rate of heart failure and mortality19. 
We failed to find any significant association between Hp 
genotype and the presence of CVD in the diabetic patients 
studied here. However, when we compared the frequency of 
genotypes with other clinical and laboratory parameters, we 
found a significantly higher prevalence of Hp2-1 patients among 
those with RH, together with higher SBP, DBP and total and LDL-
cholesterol plasma levels.
The pathogenesis of human hypertension is considered 
complex and multifactorial and results from the combined 
effect of predisposing genetic and environmental risk factors34. 
Surya Prabha et al35 suggested that patients with the Hp 2-2 
phenotype had a higher risk for essential hypertension and 
hypertension in association with ischemic heart disease than 
normal subjects. Observing that there was a significant decrease 
in the mean levels of serum Hp in subjects with hypertension 
compared with those without hypertension, they suggested the 
possibility of intravascular hemolysis due to vascular damage in 
SAH patients, and that this could lead to further complications35. 
Similarly, Delanghe et al36 observed that hypertensive patients 
with the Hp2-2 phenotype need more complex combinations 
of antihypertensive drugs to reduce their blood pressure36. 
However, Depypere et al37 studying patients with preeclampsia, 
concluded that the Hp 1-1 phenotype is associated with more 
severe hypertension. As far as we know, only one previous study 
in the literature has investigated the existence of an association 
between RH and Hp polymorphism. In this study, Delanghe et 
al36 found that hypertensive patients with the Hp 2-2 phenotype 
are at higher risk of developing RH than those with Hp2-1 and 
Hp1-1 phenotype. All these studies, however, were carried out 
in nondiabetic patients.
Previous studies have found an association between the 
Hp2-1 phenotype and CVD. Fröhlander and Johnson38 analyzed 
patients with acute myocardial infarction and found higher 
serum cholesterol levels in those with the Hp2-1 phenotype. 
Hochberg et al39 observed that diabetic patients with the Hp 2-1 
phenotype have more coronary artery collaterals than diabetic 
patients with the Hp2-2 phenotype in the setting of coronary 
artery disease. Densem et al40 investigating the association 
between Hp phenotype and the development of cardiac 
transplant vasculopathy, observed that recipients with the Hp2-
1 phenotype were more likely to develop angiographic disease. 
The authors suggested that the intermediate functions of Hp in 
Hp2-1 recipients may put these patients at disadvantage because 
Table 4 – Unadjusted univariate logistic regression analysis and 
multivariate logistic regression analysis adjusted for sex and age 
of the association between RH and the independent variables in 
T2DM patients
Univariate regression Odds  ratio p-values
Age (years) 1.037 0.1781
Sex (women versus men) 2.211 0.0543
Ethnic group (white versus black) 1.083 0.8906
Obesity (yes versus no) 1.646 0.2663
Total Cholesterol (mg/dL) 1.002 0.7114
LDL (mg/dL) 1.000 0.9424
Triglycerides (mg/dL) 1.003 0.1838
Serum creatinine (mg/dL) 1.416 0.2840
Vascular complications (presence versus 
absence) 0.869 0.7321
Hp genotype (Hp1-1 versus Hp2-2) 1.500 0.4368
Hp genotype (Hp2-1 versus Hp2-2) 4.210 0.0041
Multivariate regression Odds  ratio p-values
Age (years) 1.040 0.1693
Sex (women versus men) 2.129 0.0839
Hp genotype (Hp1-1 versus Hp2-2) 1.601 0.3860
Hp genotype (Hp2-1 versus Hp2-2) 4.271 0.0046
Although, due to the size sample, our data support the hypothesis of an 
association between the Hp genotypes and cardiovascular complications 
only for the patients studied here, the existence of an association between 
the Hp2-1 genotype and RH can be extended to the general population of 
T2 diabetics (test power higher than 80%).
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Conclusions
In conclusion, although Hp genotype cannot be used as 
a genetic marker for predisposition to CVD in this Brazilian 
population, our results suggest that T2DM patients with the Hp2-1 
genotype have higher susceptibility to RH. 
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of the intermediate effectiveness of the Hp2-1 protein, which 
appears to be less effective than the Hp protein in Hp1-1 and 
Hp2-2 homozygotes40. Our findings agree with this hypothesis 
regarding predisposition to develop RH. 
Although this study lacks a control group well matched 
for age, our findings make a significant contribution to the 
understanding of the role of Hp genotype in DM as they show 
that the T2DM patients with the Hp2-1 genotype studied 
here had a high prevalence of RH and high cholesterol levels. 
The frequency of this genotype in the patients with RH was 
55.8%, while in patients without RH it was 26.5%. In the 
latter group, the frequency of the Hp2-2 genotype was 44.1%, 
against 22.1% in the former. Further research is required to 
clarify the relationship between the structural and functional 
properties of Hp and a predisposition to develop RH and 
elevated cholesterol levels, as well as the role of this protein 
in hypertension and its complications. 
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